We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

82 hedge funds and large institutions have $335M invested in Relmada Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,377% more call options, than puts

Call options by funds: $17M | Put options by funds: $1.15M

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

12% more capital invested

Capital invested by funds: $298M → $335M (+$36.7M)

3% more funds holding

Funds holding: 80 → 82 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.4% less ownership

Funds ownership: 57.33% → 56.93% (-0.4%)

27% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 26

Holders
82
Holders Change
+2
Holders Change %
+2.5%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
12
Increased
19
Reduced
26
Closed
10
Calls
$17M
Puts
$1.15M
Net Calls
+$15.8M
Net Calls Change
+$9.14M

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$10.2M
2
VA
VR Adviser
New York
+$6.46M
3
CAC
Cowen and Company
New York
+$5.84M
4
SSA
Schonfeld Strategic Advisors
New York
+$1.91M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$8.57M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.94M
3
ACP
Acuta Capital Partners
California
-$3.85M
4
Wells Fargo
Wells Fargo
California
-$1.08M
5
Aviva
Aviva
United Kingdom
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
76
Cubist Systematic Strategies
Connecticut
$1K -$20.8K -595 -95%
Daiwa Securities Group
77
Daiwa Securities Group
Japan
$1K – – –
GEA
78
Glen Eagle Advisors
New Jersey
$880 – – –
AIG
79
American International Group
New York
$301 +$770 +22 +0.3%
BBHC
80
Brown Brothers Harriman & Co
New York
$211 – – –
Nisa Investment Advisors
81
Nisa Investment Advisors
Missouri
$172 – – –
Invesco
82
Invesco
Georgia
– -$8.57M -267,155 Closed
ACP
83
Acuta Capital Partners
California
– -$3.85M -120,000 Closed
Aviva
84
Aviva
United Kingdom
– -$1.08M -33,559 Closed
HS
85
HighVista Strategies
Massachusetts
– -$720K -22,450 Closed
SG Americas Securities
86
SG Americas Securities
New York
– -$546K -17,034 Closed
WMSA
87
Weiss Multi-Strategy Advisers
New York
– -$270K -8,434 Closed
Squarepoint
88
Squarepoint
New York
– -$229K -7,130 Closed
Ensign Peak Advisors
89
Ensign Peak Advisors
Utah
– -$82K -2,560 Closed
PAM
90
Panagora Asset Management
Massachusetts
– -$6K -195 Closed
VAIA
91
Virtus Alternative Investment Advisers
Connecticut
– -$5K -150 Closed
1 2 3
4

RLMD Hedge Fund Activity: Q1 2021 in Review

82 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2021, worth a combined $335M — up 12% from $298M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RLMD positions and 10 closed out — a net gain of 2 holders — while 19 added to existing stakes and 26 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $10.2M. The largest seller was Invesco, exiting entirely with an estimated $8.57M sold.

  • 82 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2021, up from 80 in Q4 2020.
  • Funds reported $335M of Relmada Therapeutics stock for Q1 2021, up 12% quarter-over-quarter.
  • 12 funds opened new Relmada Therapeutics positions in Q1 2021 and 10 closed out, a net change of +2 holders.
  • The largest Relmada Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $10.2M added.
  • The largest Relmada Therapeutics seller in Q1 2021 was Invesco, an estimated $8.57M sold.

Based on aggregated 13F filings for Q1 2021.